HomeTrialNCT03838926
🔬NCT03838926Phase 1RECRUITING

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Study Summary

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment42 participants
Primary Completion
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188525+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.